NEW YORK--(BUSINESS WIRE)--Medivo Inc., a health monitoring company for physicians and their patients, today announced the launch of HAE Monitor, a free mobile and web-based application for people with hereditary angioedema (HAE). The platform allows HAE patients to easily and accurately track symptoms and deliver reports to their physicians for optimal treatment.
HAE Monitor is available as a web-based app or for download in the iTunes® App Store and Android™ Market. The app enables people to connect with participating physicians, who can receive regular patient updates to make better-informed treatment decisions. Additional features include noting questions for doctors, documenting hospitalizations, creating custom symptoms and socializing with other HAE patients.
“For people living with HAE, we are pleased to offer this unique tool designed to help patients and their doctors better understand HAE and what may trigger their attacks,” said Dr. Jason Bhan, EVP and Co-Founder of Medivo. “It also marks a continuation of Medivo’s plan to provide free, useful tools for patients to monitor their symptoms and observe changes in their chronic conditions on a daily basis.”
The new HAE Monitor app builds upon the success Medivo has achieved with its popular GI Monitor, the number one mobile disease monitoring application for IBD patients.
HAE, a potentially life-threatening genetic disease, is found in about 1 in 10,000 to 1 in 50,000 people. Symptoms include episodes of edema (swelling) in various body parts. Patients also often have bouts of excruciating abdominal pain, nausea and vomiting, which is caused by swelling in the intestinal wall.
Headquartered in New York City, Medivo is a health monitoring company dedicated to helping save and improve lives through faster and easier access to quality healthcare. The Medivo platform collects clinical data from labs and symptom data from apps and devices to help physicians provide better care and help their patients more effectively monitor their health. Medivo enables patients to better manage their health and have more meaningful interactions with their doctors through access to testing and mobile symptom monitoring tools, easy-to-understand explanations of lab results, and relevant education information. Medivo raised $7M in Series A funding in 2011 led by Safeguard Scientifics, Inc. (NYSE:SFE). For more information, visit our website at www.medivo.com, follow us on Twitter @gomedivo or Like Us on Facebook.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50470322&lang=en